INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Grant or awardVerified data

Kaul Inderjit reported NERV

Director · Minerva Neurosciences, Inc. · Minerva Neurosciences, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
12.2K
Price
—
Executed
Mar 31, 2026
Disclosed
Apr 1, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Mar 31 executedApr 1, 2026 disclosed

NERV · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NERV

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    KI
    Kaul InderjitDirector
    NERVMinerva Neurosciences, Inc.
    Grant or award
    		A—
    2,328 sh
    		Nov 2, 2026Nov 3, 2026
    traded Nov 2, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KI
    Kaul InderjitDirector
    NERVMinerva Neurosciences, Inc.
    Grant or award
    		A—
    50.0K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    OJ
    O'Connor James JosephChief Business Officer and GC
    NERVMinerva Neurosciences, Inc.
    Grant or award
    		A—
    350.8K sh
    		Apr 21, 2026Apr 22, 2026
    traded Apr 21, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KI
    Kaul InderjitDirector
    NERVMinerva Neurosciences, Inc.
    Grant or award
    		A—
    364.5K sh
    		Dec 22, 2025Dec 23, 2025
    traded Dec 22, 2025
    		+1dSEC FORM 4

    Evidence

    9
    KI
    Kaul InderjitDirector
    NERVMinerva Neurosciences, Inc.
    Grant or award
    		A—
    9,500 sh
    		Nov 14, 2025Nov 18, 2025
    traded Nov 14, 2025
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002095703-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 31, 2026
    Published
    Apr 1, 2026
    Ingested by INSIDER
    Nov 5, 04:08 UTC
    Last re-read
    Nov 5, 04:08 UTC

    Extracted facts

    Filer
    Kaul Inderjit
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Minerva Neurosciences, Inc. — Stock Option (right to buy)
    Ticker
    NERV
    Shares
    12.2K
    Price per share
    $0
    Execution date (reported)
    Mar 31, 2026
    Owned after transaction
    12.2K shares
    Days from execution to publication
    1

    What this establishes

    Kaul Inderjit filed this Form 4 reporting a grant or award of NERV on Mar 31, 2026. It became public on Apr 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Kaul Inderjitcik:0002095703
    Issuer
    Minerva Neurosciences, Inc.cik:0001598646

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.